ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1247

Pre- and Post-Diagnosis Comparison of the Patient Experience of Sjögren’s Syndrome (SS): A Linguistic Analysis of Global Social Media Conversations

Sarah N. Ali1, Dorothee Oberdhan1, Michelle M. Richardson1, Jordan Amorelli2, Amanda Martini2 and Jennifer Dandy2, 1Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, 2Real Chemistry, New York, NY

Meeting: ACR Convergence 2024

Keywords: Disease Activity, Patient reported outcomes, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Patient Outcomes, Preferences, & Attitudes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Patients with Sjögren’s Syndrome (SS) often undergo a prolonged and complex path to diagnosis and experience symptom, disease and treatment burdens with multiple co-morbid conditions that impact patient lives. However, little is known about the patient experience of SS prior to and after diagnosis. This ethnographic study aimed to understand the global patient experience of SS, particularly symptom burden and life impact, as reported in social media posts pre- and post-diagnosis to better inform the design and use of patient experience data in future clinical trials.

Methods: A social listening methodology captured global public social media posts from 1/1/2023-12/31/2023, using treatment- and disease-related search terms and technologies such as web crawlers and data partnerships. Posts discussed an SS patient’s experience with the following: symptoms, life impact, comorbid conditions and/or treatment. Sociolinguists analyzed the posts in the native language using qualitative and quantitative methods. A single post could report multiple patient experience characteristics. This analysis focused on disease symptoms and life impacts.

Results: A total of 1,044 posts described the experience of SS globally from identifiable patients (96%), caregivers (4%) and health care professionals (< 1%). Posts were on X (58%), forums (31%) and Reddit (11%). Post volume by country were the United States (33.5%) Japan (21.6%), Germany (10.8%), the United Kingdom (9.6%), Canada (9.6%), France (5.7%), Spain (3.9%), South Korea (2.6%), Australia (2.4%) and Italy (< 0.3%). Impacts of the disease were described as challenges to daily functioning (e.g., inability to do daily tasks/excercise) (19%), emotional impact (e.g., negative emotions due to the disease and its care, feelings of frustration, anger, stress, sadness due to chronic fatigue and pain, loss of hobbies, isolation, financial difficulties) (16%) and health vulnerability (e.g., concerns about being immunocompromised) (11%). Table 1 compares symptoms and Table 2 compares the most common symptom by country.

Conclusion: This linguistic analysis of global social media posts showed that the SS patient experience differs pre- and post-diagnosis and by country. The increase in pain and fatigue mentions suggests a decline in quality of life, despite a diagnosis and underscores the impact of symptoms that may be challenging to treat. Although, dryness, gastrointestinal and mouth/throat issues declined slightly, reports of dental problems persisted, underscoring long-term impact. These findings provide an understanding of SS patient experience that can inform the design of patient experience data in SS clinical trials. Future research on the natural history of SS is needed to better understand its utility.

Supporting image 1

Supporting image 2


Disclosures: S. Ali: Otsuka, 3; D. Oberdhan: Otsuka, 3; M. Richardson: GlaxoSmithKlein(GSK), 2, Integra, 11, Otsuka Pharmaceutical Development and Commercialization, 2; J. Amorelli: ; A. Martini: None; J. Dandy: None.

To cite this abstract in AMA style:

Ali S, Oberdhan D, Richardson M, Amorelli J, Martini A, Dandy J. Pre- and Post-Diagnosis Comparison of the Patient Experience of Sjögren’s Syndrome (SS): A Linguistic Analysis of Global Social Media Conversations [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/pre-and-post-diagnosis-comparison-of-the-patient-experience-of-sjogrens-syndrome-ss-a-linguistic-analysis-of-global-social-media-conversations/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pre-and-post-diagnosis-comparison-of-the-patient-experience-of-sjogrens-syndrome-ss-a-linguistic-analysis-of-global-social-media-conversations/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology